The FDA has approved a 0.3% foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of seborrheic dermatitis in patients ≥9 years old. Roflumilast is the first PDE4 inhibitor to be approved in the US for this indication. It is also available in a 0.3% cream formulation (Zoryve) for treatment of plaque psoriasis and in an oral formulation (Daliresp, and generics) for treatment of chronic obstructive pulmonary disease.1,2 A 0.15% cream formulation for treatment of atopic dermatitis in patients ≥6 years old will be reviewed by...
ISSUE
The FDA has approved Cabtreo (Bausch Health), a gel containing the retinoid adapalene, the oxidizing agent benzoyl peroxide, and the antibiotic clindamycin, for treatment of acne vulgaris in patients ≥12 years old. Cabtreo is the first three-drug topical formulation to become available in the US for treatment of acne.
STANDARD TREATMENT — Topical retinoids, benzoyl peroxide, and antibiotics are commonly used in various combinations for first-line treatment of acne. Retinoid/antimicrobial combinations are more effective than either component alone, especially in patients with inflammatory acne. For moderate to severe inflammatory acne that has not responded to topical combination therapy, addition of an oral tetracycline is recommended. The most effective drug for treatment of inflammatory acne is the oral retinoid …